← Insider buys

Jay T Flatley has bought stock on 4 days since May 2017

Director at Rivian Automotive, Inc., and 3 other companies

SEC CIK 0001189130 · Filings on SEC.gov ↗

$2.8MBought
$165.5MSold
Mar 5Last buy

Jay T Flatley's record

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Companies

Every filing

90 filings since Jan 2016, newest first

RIVNBuy

Rivian Automotive, Inc. / De

Director

$25K+1.0%Mar 5
ZYBuy

Zymergen Inc.

COB, Acting CEO

$1.0M+223.0%Nov 19
RIVNBuy

Rivian Automotive, Inc. / De

Director

$1.6M+61.0%Nov 17
ILMNSell

Illumina, Inc.

Director

$1.5M−3.0%May 20
ILMNSell

Illumina, Inc.

Director

$1.5M−2.0%May 6
ILMNSell

Illumina, Inc.

Director

$1.6M−2.0%Apr 22
ILMNSell

Illumina, Inc.

Director

$1.7M−2.0%Apr 7
ILMNSell

Illumina, Inc.

Director

$1.7M−2.0%Mar 18
ILMNSell

Illumina, Inc.

Director

$1.8M−2.0%Mar 4
ILMNSell

Illumina, Inc.

Director

$2.3M−2.0%Feb 18
ILMNSell

Illumina, Inc.

Director

$1.8M−2.0%Feb 3
ILMNSell

Illumina, Inc.

Director

$1.5M−2.0%Jan 21
ILMNSell

Illumina, Inc.

Director

$1.5M−2.0%Jan 6
ILMNSell

Illumina, Inc.

Director

$1.4M−2.0%Dec 16
ILMNSell

Illumina, Inc.

Director

$1.3M−2.0%Dec 2
ILMNSell

Illumina, Inc.

Director

$891K−1.0%Nov 19
ILMNSell

Illumina, Inc.

Director

$892K−1.0%Nov 4
ILMNSell

Illumina, Inc.

Director

$1.3M−2.0%Oct 22
ILMNSell

Illumina, Inc.

Director

$324KOct 8
ILMNSell

Illumina, Inc.

Director

$953K−1.0%Oct 7
ILMNSell

Illumina, Inc.

Director

$1.4M−2.0%Sep 17
ILMNSell

Illumina, Inc.

Director

$1.4M−2.0%Sep 2
ILMNSell

Illumina, Inc.

Director

$1.4M−2.0%Aug 20
ILMNSell

Illumina, Inc.

Director

$1.6M−2.0%Aug 5
ILMNSell

Illumina, Inc.

Director

$1.6M−2.0%Jul 22
ILMNSell

Illumina, Inc.

Director

$1.5M−2.0%Jul 8
ILMNSell

Illumina, Inc.

Director

$1.4M−2.0%Jun 17
ILMNSell

Illumina, Inc.

Director

$1.5M−2.0%Jun 3
ILMNSell

Illumina, Inc.

Director

$1.4M−2.0%May 20
ILMNSell

Illumina, Inc.

Director

$931K−1.0%May 7
ILMNSell

Illumina, Inc.

Director

$932K−1.0%Apr 22
ILMNSell

Illumina, Inc.

Director

$1.5M−2.0%Apr 8
ILMNSell

Illumina, Inc.

Director

$555K−1.0%Mar 4
ILMNSell

Illumina, Inc.

Director

$935K−1.0%Aug 29
ILMNSell

Illumina Inc

Director

$952K−1.0%Aug 15
ILMNSell

Illumina Inc

Director

$1.0M−1.0%Jul 25
ILMNSell

Illumina Inc

Director

$1.2M−1.0%Jul 12
ILMNSell

Illumina Inc

Director

$1.2M−1.0%Jun 28
ILMNSell

Illumina Inc

Director

$1.1M−1.0%Jun 14
ILMNSell

Illumina Inc

Director

$1.0M−1.0%May 24
ILMNSell

Illumina Inc

Director

$1.1M−1.0%May 10
ILMNSell

Illumina Inc

Director

$1.1M−1.0%Apr 26
ILMNSell

Illumina Inc

Director

$1.0M−1.0%Apr 12
ILMNSell

Illumina Inc

Director

$2.0M−2.0%Mar 29
ILMNSell

Illumina Inc

Director

$990K−1.0%Mar 1
ILMNSell

Illumina Inc

Director

$969K−1.0%Feb 14
ILMNSell

Illumina Inc

Director

$1.0M−1.0%Jan 25
ILMNSell

Illumina Inc

Director

$977K−1.0%Jan 11
ILMNSell

Illumina Inc

Director

$904K−1.0%Dec 28
ILMNSell

Illumina Inc

Director

$1.1M−1.0%Dec 13
About Jay T Flatley

Jay T. Flatley is an accomplished technology executive serving as an Independent Class III Director on the Board of Directors of Rivian Automotive, Inc. (RIVN) since May 2021, where he contributes to Audit and Compensation committees, leveraging his expertise in finance, controls, and governance.( At age 73, he is recognized for his independence under Nasdaq rules and active participation in board activities.(

Flatley holds a B.A. in Economics from Claremont McKenna College and B.S. and M.S. in Industrial Engineering from Stanford University.( His career highlights include co-founding and leading Molecular Dynamics as President and CEO from 1994 to 1998, culminating in its sale to Amersham Pharmacia Biotech, and a transformative tenure at Illumina, Inc., where he served as CEO from 1999 to 2016, scaling revenue from $1.3 million in 2000 to $2.2 billion in 2015 (64% CAGR), pioneering next-generation sequencing via the 2006 Solexa acquisition, and earning accolades like MIT Technology Review's 'World’s Smartest Company' in 2014.( He later acted as CEO of Zymergen (2021-2022) and holds current roles such as Director at Denali Therapeutics and Trustee at The Salk Institute.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.